Gastrointestinal adverse events associated with use of biologic therapies available for psoriasis: a systematic review of pharmacovigilance studies

Biologic therapies have revolutionized psoriasis treatment in the past decade. While clinical trials identified diarrhea and gastrointestinal (GI) upset as common adverse events (AEs), there is limited characterization of these events beyond inflammatory bowel disease (IBD). In contrast to clinical trials with strict inclusion criteria and safety analyses confounded by drop-out rates, pharmacovigilance studies evaluate spontaneous real-world AE reports of a given population. This systematic review examines pharmacovigilance evidence regarding rate and onset of GI events with psoriasis biologic therapies.